GlassScriptPhysician profile
Holly A Arnold
NPI 1083876148
$1,287.22
in general payments reported to CMS, 2019-2025
26 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $234 · 2023: $266 · 2024: $360 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $296.18 | 2022-2024 | Jornay Pm |
| Mylan Specialty L.P. | $158.45 | 2021-2024 | Yupelri |
| Dexcom, INC. | $80.37 | 2022-2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $74.47 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.49 | 2024 | Caplyta |
| Abbvie INC. | $56.71 | 2022-2024 | |
| Lilly USA, LLC | $49.04 | 2021-2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $47.10 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.84 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $43.81 | 2023-2024 | Gardasil 9, Vaxelis, Proquad |
| Astrazeneca Pharmaceuticals LP | $43.40 | 2021 | |
| Pfizer INC. | $42.46 | 2023-2024 | |
| Amgen INC. | $38.62 | 2022-2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $34.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $28.18 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.36 | 2024 | Trelegy Ellipta, Arexvy |
| Eisai INC. | $18.76 | 2021 | |
| Cmp Pharma, INC. | $18.31 | 2021 | |
| Cipher Pharmaceuticals US LLC | $18.07 | 2025 | Natroba, Spinosad |
| Janssen Pharmaceuticals, INC | $18.05 | 2021 | |
| Corcept Therapeutics | $17.82 | 2021 | |
| Astellas Pharma US INC | $17.43 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $16.42 | 2024 | Gemtesa |
| Medline Industries LP | $15.95 | 2023 | |
| Amarin Pharma, INC. | $15.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.